Trials / Completed
CompletedNCT02342184
Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Japan Blood Products Organization · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
This study will carry out to assess the efficacy of GB-0998 (intravenous immunoglobulin;400mg/kg/day for five days) in the treatment of the Guillain-Barré Syndrome based on the changes in Hughes Functional Grade (FG) as primary endpoint, and in addition, to assess the safety of GB-0998.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GB-0998 |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2015-09-01
- Completion
- 2015-09-01
- First posted
- 2015-01-19
- Last updated
- 2016-02-04
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT02342184. Inclusion in this directory is not an endorsement.